22.89
전일 마감가:
$23.29
열려 있는:
$23.185
하루 거래량:
197.62K
Relative Volume:
0.13
시가총액:
$1.44B
수익:
-
순이익/손실:
$-107.85M
주가수익비율:
-10.36
EPS:
-2.21
순현금흐름:
$-106.82M
1주 성능:
+9.88%
1개월 성능:
+20.38%
6개월 성능:
-44.65%
1년 성능:
-33.87%
베라 테라 Stock (VERA) Company Profile
명칭
Vera Therapeutics Inc
전화
650-770-0077
주소
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
VERA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
VERA
Vera Therapeutics Inc
|
22.90 | 1.44B | 0 | -107.85M | -106.82M | -2.21 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
444.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
528.53 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
318.04 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
560.07 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
240.14 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
베라 테라 Stock (VERA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-05-05 | 재개 | H.C. Wainwright | Buy |
2025-02-04 | 개시 | Wolfe Research | Outperform |
2025-01-28 | 개시 | Goldman | Buy |
2024-11-21 | 개시 | Wells Fargo | Overweight |
2024-10-16 | 개시 | Scotiabank | Sector Outperform |
2024-01-25 | 개시 | Oppenheimer | Outperform |
2024-01-08 | 개시 | Cantor Fitzgerald | Overweight |
2023-12-18 | 개시 | Raymond James | Outperform |
2023-11-10 | 업그레이드 | Jefferies | Hold → Buy |
2023-08-16 | 개시 | Guggenheim | Buy |
2023-01-04 | 다운그레이드 | Jefferies | Buy → Hold |
2023-01-04 | 다운그레이드 | Wedbush | Outperform → Neutral |
2022-07-12 | 개시 | JP Morgan | Overweight |
2022-05-02 | 개시 | H.C. Wainwright | Buy |
2022-04-19 | 개시 | Wedbush | Outperform |
모두보기
베라 테라 주식(VERA)의 최신 뉴스
Vera Therapeutics Inc put volume heavy and directionally bearish - TipRanks
Analysts Can't Get Enough of These Little-Known Biopharma Stocks - Investing.com
Transcript : Vera Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 03 - marketscreener.com
Vera Therapeutics (VERA) Sees Surge in Bullish Options Activity | VERA Stock News - GuruFocus
Vera Therapeutics reports inducement grants under Nasdaq listing rule - MarketScreener
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Vera Therapeutics Expands Team with 17 New Hires, Awards Major Stock Options Worth $6M - Stock Titan
H.C. Wainwright maintains $85 target on Vera Therapeutics stock By Investing.com - Investing.com Canada
Wedbush Cuts Price Target on Vera Therapeutics to $23 From $32, Keeps Neutral Rating - marketscreener.com
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Sold by Wellington Management Group LLP - Defense World
California State Teachers Retirement System Acquires 6,749 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics (NASDAQ:VERA) Shares Gap Down – Should You Sell? - Defense World
Biotech Stocks To Watch Today – June 6th - Defense World
Otsuka’s IgAN Data Top Some Vera Results, But To What End? - insights.citeline.com
Vera Therapeutics (VERA) Drops 32% After Trial Results Disappoin - GuruFocus
Vera Therapeutics (VERA) Stock Plummets Over 29% in Major Sell-Off - Daily Chhattisgarh News
Biotech Stock Vera Is Slumping After Monster Gain - Barron's
Vera Therapeutics stock sinks following competitor’s successful trial By Investing.com - Investing.com Nigeria
Vera Therapeutics stock sinks following competitor’s successful trial - Investing.com Australia
Vera stock drops as Otsuka bests with IgAN drug (VERA:NASDAQ) - Seeking Alpha
Bank of America Corp DE Sells 106,673 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Research Analysts Offer Predictions for VERA FY2027 Earnings - Defense World
IgA Nephropathy Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approval, Treatment Market, Revenue, Statistics, Therapies, and Companies by DelveInsight - The Globe and Mail
Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins - insights.citeline.com
Scotiabank Increases the Price Target for Vera Therapeutics by $10 - MSN
FY2025 EPS Forecast for Vera Therapeutics Reduced by Analyst - Defense World
(VERA) Trading Advice - news.stocktradersdaily.com
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Vera Therapeutics Enters $500M Credit Facility As It Nears FDA Filing For Kidney Disease Drug: Retail Sees Stock Touching $40 - MSN
Clinical-Stage Biotech Vera Therapeutics Joins Elite Goldman Sachs Healthcare Conference Lineup - Stock Titan
Latham & Watkins Advises Vera Therapeutics in US$500 Million Credit Facility With Oxford Finance - Latham & Watkins LLP
Vera Therapeutics Atacicept: Promising Step In IgAN, But Crowded Road Ahead (Rating Downgrade) - Seeking Alpha
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans - GlobeNewswire
Equities Analysts Set Expectations for VERA Q2 Earnings - Defense World
Vera Therapeutics (NASDAQ:VERA) Sees Large Volume Increase on Analyst Upgrade - Defense World
Vera Therapeutics eyes half billion dollars after kidney drug study - The Business Journals
Vera Therapeutics (VERA) Price Target Increased Amid Positive Tr - GuruFocus
Vera Therapeutics Enters $500M Credit Facility As It Nears FDA Filing For Kidney Disease Drug: Retail Sees Stock Touching $40 By Stocktwits - Investing.com India
Vera Therapeutics (VERA) Secures $500 Million Credit Facility - GuruFocus
Vera Therapeutics (VERA) Sees Price Target Boost Following Positive Trial Results | VERA Stock News - GuruFocus
Vera Therapeutics Secures $500M Loan Agreement - TipRanks
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 ... - Bluefield Daily Telegraph
Vera Therapeutics Lands Massive $500M Financing Deal as FDA Filing for Kidney Drug Approaches - Stock Titan
Two Sigma Investments LP Sells 7,102 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics (NASDAQ:VERA) PT Set at $65.00 by Scotiabank - Defense World
Vera Therapeutics (NASDAQ:VERA) Given New $85.00 Price Target at HC Wainwright - Defense World
Why Vera Therapeutics, Inc. (VERA) Skyrocketed On Monday - Yahoo Finance
These 10 Stocks Blew Past Expectations - Insider Monkey
Vera Therapeutics (NASDAQ:VERA) Shares Gap Up After Analyst Upgrade - Defense World
Vera Therapeutics: Primary endpoint was met in ORIGIN Phase 3 trial of atacicept - TipRanks
H.C. Wainwright ups Vera Therapeutics target on ‘home run’ data - TipRanks
베라 테라 (VERA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
베라 테라 주식 (VERA) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
ENRIGHT PATRICK G | Director |
Jun 24 '25 |
Buy |
22.35 |
40,607 |
907,635 |
3,596,593 |
Fordyce Marshall | PRESIDENT AND CEO |
Feb 21 '25 |
Sale |
27.89 |
10,613 |
296,032 |
213,740 |
Fordyce Marshall | PRESIDENT AND CEO |
Feb 26 '25 |
Sale |
27.65 |
9,075 |
250,882 |
204,665 |
자본화:
|
볼륨(24시간):